[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjXSRzrnQ9yEETWYcVzjDyUpT8aPv3DGxQyv3U9tU0Gg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":75,"rows":82},"Corcept Therapeutics",[4],73,false,9,14,7844,5,[13,16,19,22,25,27,29,32],{"name":14,"count":15},"Healthy",22,{"name":17,"count":18},"Cushing's Syndrome",7,{"name":20,"count":21},"Nonalcoholic Steatohepatitis (NASH)",6,{"name":23,"count":24},"Major Depressive Disorder",4,{"name":26,"count":24},"Cushing Syndrome",{"name":28,"count":24},"Hypercortisolism",{"name":30,"count":31},"Healthy Adults",3,{"name":33,"count":31},"Psychotic Disorders",[35,40,45,50,55,59,62,66,71],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05257408","Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","2025-03-24","Nab-paclitaxel 80 mg\u002Fm^2",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06947304","Evaluation of Miricorilant on Liver Fat in Patients With MASLD","2026-05","Miricorilant",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06906341","Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","2026-08","Relacorilant 150 mg once daily",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07276373","Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","2026-09","Nenocorilant 200 mg",{"nctId":56,"briefTitle":57,"date":53,"intervention":58},"NCT05407324","Dazucorilant in Patients With Amyotrophic Lateral Sclerosis","Dazucorilant 300 mg",{"nctId":60,"briefTitle":61,"date":53,"intervention":44},"NCT06108219","A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis\u002FMetabolic Dysfunction-Associated Steatohepatitis (MONARCH)",{"nctId":63,"briefTitle":64,"date":65,"intervention":44},"NCT07553663","Evaluating the Pharmacokinetics and Safety of Miricorilant","2026-10-30",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03604198","Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome","2026-12","relacorilant",{"nctId":72,"briefTitle":73,"date":74,"intervention":49},"NCT07259317","Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","2027-07",[76,77,78,79,80,81],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[83,132,154,176,257,378,420,444,462,480,498,516,534,552,570,596,757,787,805,823,841,859,894,919,945,972,990,1061,1083,1113,1150,1186,1204,1222,1240,1258,1276,1294,1312,1330,1348,1366,1384,1402,1420,1438,1456,1474,1492,1510,1528,1546,1564,1582,1600,1618,1636,1663,1681,1699,1724,1742,1760,1787,1805,1823,1841,1867,1885,1909,1927,1945,1976,2002,2020,2038,2061,2085,2120,2138,2156,2174,2192,2210,2228,2246,2264,2282,2300,2318,2336,2354,2372,2390,2408,2426,2444,2467,2485,2503,2526,2544],{"intervention":49,"totalTrials":31,"cells":84},{"EARLY_PHASE1":85,"PHASE1":88,"PHASE2":90,"PHASE3":115,"PHASE4":128,"NA":130},{"trials":86,"activeCount":87},[],0,{"trials":89,"activeCount":87},[],{"trials":91,"activeCount":114,"soonestReadout":48},[92,104],{"nctId":46,"briefTitle":47,"status":93,"phases":94,"primaryCompletion":48,"completion":69,"start":95,"enrollment":96,"conditions":97,"interventions":102},"RECRUITING",[78],"2025-04-11",270,[98,99,100,101],"Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Neoplasms","Endometrial Cancer",[49,39,103],"Bevacizumab 10 mg\u002Fkg",{"nctId":72,"briefTitle":73,"status":93,"phases":105,"primaryCompletion":74,"completion":74,"start":106,"enrollment":107,"conditions":108,"interventions":111},[78],"2026-01-27",60,[109,110],"Adenocarcinoma","Carcinoma, Pancreatic Ductal",[49,112,113],"Nab-paclitaxel 100 mg\u002Fm^2","Gemcitabine 1000 mg\u002Fm^2",2,{"trials":116,"activeCount":127,"soonestReadout":38},[117],{"nctId":36,"briefTitle":37,"status":118,"phases":119,"primaryCompletion":38,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":126},"ACTIVE_NOT_RECRUITING",[79],"2026-03","2022-06-29",381,[124,125,100],"Ovarian Neoplasm","Fallopian Tube Neoplasms",[39,49,112],1,{"trials":129,"activeCount":87},[],{"trials":131,"activeCount":87},[],{"intervention":39,"totalTrials":114,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":144,"PHASE4":150,"NA":152},{"trials":135,"activeCount":87},[],{"trials":137,"activeCount":87},[],{"trials":139,"activeCount":127,"soonestReadout":48},[140],{"nctId":46,"briefTitle":47,"status":93,"phases":141,"primaryCompletion":48,"completion":69,"start":95,"enrollment":96,"conditions":142,"interventions":143},[78],[98,99,100,101],[49,39,103],{"trials":145,"activeCount":127,"soonestReadout":38},[146],{"nctId":36,"briefTitle":37,"status":118,"phases":147,"primaryCompletion":38,"completion":120,"start":121,"enrollment":122,"conditions":148,"interventions":149},[79],[124,125,100],[39,49,112],{"trials":151,"activeCount":87},[],{"trials":153,"activeCount":87},[],{"intervention":112,"totalTrials":114,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":166,"PHASE4":172,"NA":174},{"trials":157,"activeCount":87},[],{"trials":159,"activeCount":87},[],{"trials":161,"activeCount":127,"soonestReadout":74},[162],{"nctId":72,"briefTitle":73,"status":93,"phases":163,"primaryCompletion":74,"completion":74,"start":106,"enrollment":107,"conditions":164,"interventions":165},[78],[109,110],[49,112,113],{"trials":167,"activeCount":127,"soonestReadout":38},[168],{"nctId":36,"briefTitle":37,"status":118,"phases":169,"primaryCompletion":38,"completion":120,"start":121,"enrollment":122,"conditions":170,"interventions":171},[79],[124,125,100],[39,49,112],{"trials":173,"activeCount":87},[],{"trials":175,"activeCount":87},[],{"intervention":44,"totalTrials":18,"cells":177},{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":221,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":179,"activeCount":87},[],{"trials":181,"activeCount":114,"soonestReadout":43},[182,191,202,213],{"nctId":63,"briefTitle":64,"status":93,"phases":183,"primaryCompletion":65,"completion":65,"start":184,"enrollment":185,"conditions":186,"interventions":190},[77],"2026-04-30",15,[20,187,188,189],"Metabolic Dysfunction-Associated Steatohepatitis (MASH) \u002F Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis","Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Non-alcoholic Fatty Liver Disease (NAFLD)",[44],{"nctId":192,"briefTitle":193,"status":194,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT05553470","Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant","COMPLETED",[77],"2024-09-13","2022-03-03",19,[200],"Non-alcoholic Steatohepatitis (NASH)",[44],{"nctId":203,"briefTitle":204,"status":194,"phases":205,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":211},"NCT05712265","Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant",[77],"2023-02-23","2023-01-24",26,[210,200],"Antipsychotic Induced Weight Gain",[44,212],"Fluvoxamine",{"nctId":41,"briefTitle":42,"status":93,"phases":214,"primaryCompletion":43,"completion":43,"start":215,"enrollment":216,"conditions":217,"interventions":220},[77],"2025-08-22",8,[20,218,219,189],"Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",[44],{"trials":222,"activeCount":127,"soonestReadout":53},[223,230,240],{"nctId":60,"briefTitle":61,"status":118,"phases":224,"primaryCompletion":53,"completion":53,"start":225,"enrollment":226,"conditions":227,"interventions":229},[78],"2023-10-25",175,[20,228],"Metabolic Dysfunction-associated Steatohepatitis (MASH)",[44,44],{"nctId":231,"briefTitle":232,"status":233,"phases":234,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":239},"NCT03823703","Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)","TERMINATED",[78],"2021-04-05","2020-11-04",12,[20],[44],{"nctId":241,"briefTitle":242,"status":194,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":250},"NCT03818256","A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications",[78],"2022-06-17","2022-07-06","2019-12-04",71,[249],"Antipsychotic-induced Weight Gain (AIWG)",[44],{"trials":252,"activeCount":87},[],{"trials":254,"activeCount":87},[],{"trials":256,"activeCount":87},[],{"intervention":258,"totalTrials":259,"cells":260},"Relacorilant",10,{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":331,"PHASE3":353,"PHASE4":374,"NA":376},{"trials":262,"activeCount":87},[],{"trials":264,"activeCount":87},[265,276,291,302,313,322],{"nctId":266,"briefTitle":267,"status":194,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":185,"conditions":272,"interventions":274},"NCT04373265","Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)",[77],"2023-10-17","2024-01-12","2020-09-30",[273],"Adrenocortical Carcinoma",[258,275],"Pembrolizumab",{"nctId":277,"briefTitle":278,"status":194,"phases":279,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":285},"NCT03457597","Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s",[77],"2018-04-15","2018-04-28","2018-03-06",27,[14],[286,287,288,289,290,258],"Midazolam hydrochloride","Metoprolol tartrate","Pioglitazone hydrochloride","Tolbutamide","Omeprazole",{"nctId":292,"briefTitle":293,"status":194,"phases":294,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":300},"NCT05347979","Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants",[77],"2022-07-19","2022-05-25",30,[26,299],"Neoplasms",[301,258],"Dabigatran Etexilate",{"nctId":303,"briefTitle":304,"status":194,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":311},"NCT04795479","T\u002FQT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers",[77],"2021-05-17","2021-07-13","2021-01-22",36,[14],[258,312],"Moxifloxacin",{"nctId":314,"briefTitle":315,"status":194,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":297,"conditions":319,"interventions":321},"NCT06094725","A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant",[77],"2020-12-14","2020-01-06",[320],"Hepatic Impairment",[258],{"nctId":323,"briefTitle":324,"status":194,"phases":325,"primaryCompletion":326,"completion":327,"start":328,"enrollment":297,"conditions":329,"interventions":330},"NCT03540836","A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants",[77],"2018-07-16","2018-07-25","2018-05-24",[14],[258,258,258],{"trials":332,"activeCount":127,"soonestReadout":69},[333,339],{"nctId":67,"briefTitle":68,"status":118,"phases":334,"primaryCompletion":69,"completion":69,"start":335,"enrollment":336,"conditions":337,"interventions":338},[78],"2018-05-07",125,[26],[70],{"nctId":340,"briefTitle":341,"status":194,"phases":342,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":351},"NCT03776812","Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[78],"2021-03-16","2023-07-12","2019-04-05",178,[348,349,350],"Recurrent Ovarian Cancer","Recurrent Fallopian Tube Carcinoma","Recurrent Primary Peritoneal Carcinoma",[258,352],"Nab-paclitaxel",{"trials":354,"activeCount":87},[355,364],{"nctId":356,"briefTitle":357,"status":194,"phases":358,"primaryCompletion":359,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":363},"NCT04308590","A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas",[79],"2024-09-19","2020-07-27",137,[28],[258],{"nctId":365,"briefTitle":366,"status":194,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":373},"NCT03697109","A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome",[79],"2024-04-08","2024-04-15","2018-11-15",152,[26],[258],{"trials":375,"activeCount":87},[],{"trials":377,"activeCount":87},[],{"intervention":379,"totalTrials":31,"cells":380},"Dazucorilant",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":403,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":382,"activeCount":87},[],{"trials":384,"activeCount":87},[385,395],{"nctId":386,"briefTitle":387,"status":194,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":393},"NCT06495944","Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants",[77],"2024-08-02","2024-05-31",21,[30],[379,394],"Itraconazole",{"nctId":396,"briefTitle":397,"status":194,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":198,"conditions":401,"interventions":402},"NCT06928779","Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant",[77],"2024-12-09","2024-10-08",[320],[379],{"trials":404,"activeCount":127,"soonestReadout":53},[405],{"nctId":56,"briefTitle":57,"status":93,"phases":406,"primaryCompletion":53,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},[78],"2027-11","2022-11-15",279,[411],"Amyotrophic Lateral Sclerosis",[58,413,379],"Dazucorilant 150 mg",{"trials":415,"activeCount":87},[],{"trials":417,"activeCount":87},[],{"trials":419,"activeCount":87},[],{"intervention":54,"totalTrials":127,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":423,"activeCount":87},[],{"trials":425,"activeCount":87},[],{"trials":427,"activeCount":127,"soonestReadout":53},[428],{"nctId":51,"briefTitle":52,"status":93,"phases":429,"primaryCompletion":53,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":434},[77,78],"2027-01","2026-01-16",50,[299],[54,435,436,437],"Nenocorilant 300 mg","Nenocorilant 400 mg","Nivolumab",{"trials":439,"activeCount":87},[],{"trials":441,"activeCount":87},[],{"trials":443,"activeCount":87},[],{"intervention":435,"totalTrials":127,"cells":445},{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":447,"activeCount":87},[],{"trials":449,"activeCount":87},[],{"trials":451,"activeCount":127,"soonestReadout":53},[452],{"nctId":51,"briefTitle":52,"status":93,"phases":453,"primaryCompletion":53,"completion":430,"start":431,"enrollment":432,"conditions":454,"interventions":455},[77,78],[299],[54,435,436,437],{"trials":457,"activeCount":87},[],{"trials":459,"activeCount":87},[],{"trials":461,"activeCount":87},[],{"intervention":436,"totalTrials":127,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":474,"PHASE4":476,"NA":478},{"trials":465,"activeCount":87},[],{"trials":467,"activeCount":87},[],{"trials":469,"activeCount":127,"soonestReadout":53},[470],{"nctId":51,"briefTitle":52,"status":93,"phases":471,"primaryCompletion":53,"completion":430,"start":431,"enrollment":432,"conditions":472,"interventions":473},[77,78],[299],[54,435,436,437],{"trials":475,"activeCount":87},[],{"trials":477,"activeCount":87},[],{"trials":479,"activeCount":87},[],{"intervention":437,"totalTrials":127,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":492,"PHASE4":494,"NA":496},{"trials":483,"activeCount":87},[],{"trials":485,"activeCount":87},[],{"trials":487,"activeCount":127,"soonestReadout":53},[488],{"nctId":51,"briefTitle":52,"status":93,"phases":489,"primaryCompletion":53,"completion":430,"start":431,"enrollment":432,"conditions":490,"interventions":491},[77,78],[299],[54,435,436,437],{"trials":493,"activeCount":87},[],{"trials":495,"activeCount":87},[],{"trials":497,"activeCount":87},[],{"intervention":103,"totalTrials":127,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":510,"PHASE4":512,"NA":514},{"trials":501,"activeCount":87},[],{"trials":503,"activeCount":87},[],{"trials":505,"activeCount":127,"soonestReadout":48},[506],{"nctId":46,"briefTitle":47,"status":93,"phases":507,"primaryCompletion":48,"completion":69,"start":95,"enrollment":96,"conditions":508,"interventions":509},[78],[98,99,100,101],[49,39,103],{"trials":511,"activeCount":87},[],{"trials":513,"activeCount":87},[],{"trials":515,"activeCount":87},[],{"intervention":58,"totalTrials":127,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":528,"PHASE4":530,"NA":532},{"trials":519,"activeCount":87},[],{"trials":521,"activeCount":87},[],{"trials":523,"activeCount":127,"soonestReadout":53},[524],{"nctId":56,"briefTitle":57,"status":93,"phases":525,"primaryCompletion":53,"completion":407,"start":408,"enrollment":409,"conditions":526,"interventions":527},[78],[411],[58,413,379],{"trials":529,"activeCount":87},[],{"trials":531,"activeCount":87},[],{"trials":533,"activeCount":87},[],{"intervention":413,"totalTrials":127,"cells":535},{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":537,"activeCount":87},[],{"trials":539,"activeCount":87},[],{"trials":541,"activeCount":127,"soonestReadout":53},[542],{"nctId":56,"briefTitle":57,"status":93,"phases":543,"primaryCompletion":53,"completion":407,"start":408,"enrollment":409,"conditions":544,"interventions":545},[78],[411],[58,413,379],{"trials":547,"activeCount":87},[],{"trials":549,"activeCount":87},[],{"trials":551,"activeCount":87},[],{"intervention":113,"totalTrials":127,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":555,"activeCount":87},[],{"trials":557,"activeCount":87},[],{"trials":559,"activeCount":127,"soonestReadout":74},[560],{"nctId":72,"briefTitle":73,"status":93,"phases":561,"primaryCompletion":74,"completion":74,"start":106,"enrollment":107,"conditions":562,"interventions":563},[78],[109,110],[49,112,113],{"trials":565,"activeCount":87},[],{"trials":567,"activeCount":87},[],{"trials":569,"activeCount":87},[],{"intervention":571,"totalTrials":127,"cells":572},"Mifepristone 300 MG [Korlym]",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":594},{"trials":574,"activeCount":87},[],{"trials":576,"activeCount":87},[],{"trials":578,"activeCount":87},[],{"trials":580,"activeCount":87},[],{"trials":582,"activeCount":87},[583],{"nctId":584,"briefTitle":585,"status":194,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT05772169","Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)",[80],"2024-11-19","2024-12-18","2023-03-31",1113,[28,592],"Diabetes Mellitus, Type 2",[571],{"trials":595,"activeCount":87},[],{"intervention":597,"totalTrials":185,"cells":598},"Mifepristone",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":636,"PHASE3":658,"PHASE4":753,"NA":755},{"trials":600,"activeCount":87},[],{"trials":602,"activeCount":87},[603,615,627],{"nctId":604,"briefTitle":605,"status":194,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":611},"NCT00698022","A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers",[77],"2009-02","2008-11",76,[14],[612,597,613,614],"Risperidone","Risperidone-matched placebo","Mifepristone-matched placebo",{"nctId":616,"briefTitle":617,"status":194,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT03508635","CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)",[77],"2015-12","2014-09",130,[14],[624,597,625,626],"CORT125134","Prednisone","Glucose",{"nctId":628,"briefTitle":629,"status":194,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":635},"NCT03258372","Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites",[77],"2017-11-29","2017-08-16",48,[14],[597],{"trials":637,"activeCount":87},[638,648],{"nctId":639,"briefTitle":640,"status":194,"phases":641,"completion":642,"start":643,"enrollment":644,"conditions":645,"interventions":647},"NCT00455442","A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain",[78],"2007-07","2007-03",57,[646],"Weight-Gain Prevention",[597],{"nctId":649,"briefTitle":650,"status":233,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT00105105","Mifepristone as Adjunctive Therapy in Alzheimer's Disease",[78],"2005-11","2003-04",160,[656],"Alzheimer's Disease",[597],{"trials":659,"activeCount":87},[660,671,680,689,697,709,718,727,738,745],{"nctId":661,"briefTitle":662,"status":663,"phases":664,"primaryCompletion":665,"start":666,"enrollment":87,"conditions":667,"interventions":669},"NCT01925092","Mifepristone in Children With Refractory Cushing's Disease","WITHDRAWN",[79],"2016-12","2013-08",[668],"Cushing's Disease",[670],"mifepristone",{"nctId":672,"briefTitle":673,"status":194,"phases":674,"primaryCompletion":675,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT00146523","An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression",[79],"2006-07","2005-05",247,[23],[597],{"nctId":681,"briefTitle":682,"status":194,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":24,"conditions":687,"interventions":688},"NCT01371565","Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome",[79],"2012-06","2012-09","2010-11",[668,17],[597],{"nctId":690,"briefTitle":691,"status":194,"phases":692,"primaryCompletion":693,"start":694,"enrollment":432,"conditions":695,"interventions":696},"NCT00569582","A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome",[79],"2011-01","2007-12",[17],[670],{"nctId":698,"briefTitle":699,"status":233,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":708},"NCT00637494","A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features",[79],"2014-06","2008-03",292,[705,706,707],"Psychotic Depression","Severe Major Depression With Psychotic Features","Psychosis",[670],{"nctId":710,"briefTitle":711,"status":194,"phases":712,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":717},"NCT00130676","A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression",[79],"2006-06","2004-09",257,[23,33],[597],{"nctId":719,"briefTitle":720,"status":194,"phases":721,"primaryCompletion":722,"completion":722,"start":676,"enrollment":723,"conditions":724,"interventions":726},"NCT00208156","A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression",[79],"2006-11",87,[725],"Depressive Disorder, Major",[597],{"nctId":728,"briefTitle":729,"status":194,"phases":730,"primaryCompletion":731,"completion":731,"start":714,"enrollment":732,"conditions":733,"interventions":734},"NCT00128479","A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression",[79],"2007-01",443,[23,33],[670,735,736,737],"mifepristone matched placebo","mifepristone 600 mg","mifepristone 1200 mg",{"nctId":739,"briefTitle":740,"status":194,"phases":741,"primaryCompletion":685,"completion":685,"start":742,"enrollment":297,"conditions":743,"interventions":744},"NCT00936741","An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome",[79],"2009-07",[17],[670],{"nctId":746,"briefTitle":747,"status":194,"phases":748,"primaryCompletion":722,"completion":722,"start":749,"enrollment":750,"conditions":751,"interventions":752},"NCT00128505","An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression",[79],"2005-08",104,[23,33],[597],{"trials":754,"activeCount":87},[],{"trials":756,"activeCount":87},[],{"intervention":352,"totalTrials":114,"cells":758},{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":769,"PHASE4":783,"NA":785},{"trials":760,"activeCount":87},[],{"trials":762,"activeCount":87},[],{"trials":764,"activeCount":87},[765],{"nctId":340,"briefTitle":341,"status":194,"phases":766,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":767,"interventions":768},[78],[348,349,350],[258,352],{"trials":770,"activeCount":87},[771],{"nctId":772,"briefTitle":773,"status":233,"phases":774,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":781},"NCT04329949","Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma",[79],"2021-08-23","2022-03-25","2020-06-30",43,[780],"Metastatic Pancreatic Ductal Adenocarcinoma",[782,352],"Relacorilant, 100 mg and 25 mg",{"trials":784,"activeCount":87},[],{"trials":786,"activeCount":87},[],{"intervention":782,"totalTrials":127,"cells":788},{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":801,"NA":803},{"trials":790,"activeCount":87},[],{"trials":792,"activeCount":87},[],{"trials":794,"activeCount":87},[],{"trials":796,"activeCount":87},[797],{"nctId":772,"briefTitle":773,"status":233,"phases":798,"primaryCompletion":775,"completion":776,"start":777,"enrollment":778,"conditions":799,"interventions":800},[79],[780],[782,352],{"trials":802,"activeCount":87},[],{"trials":804,"activeCount":87},[],{"intervention":735,"totalTrials":127,"cells":806},{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":819,"NA":821},{"trials":808,"activeCount":87},[],{"trials":810,"activeCount":87},[],{"trials":812,"activeCount":87},[],{"trials":814,"activeCount":87},[815],{"nctId":728,"briefTitle":729,"status":194,"phases":816,"primaryCompletion":731,"completion":731,"start":714,"enrollment":732,"conditions":817,"interventions":818},[79],[23,33],[670,735,736,737],{"trials":820,"activeCount":87},[],{"trials":822,"activeCount":87},[],{"intervention":736,"totalTrials":127,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":837,"NA":839},{"trials":826,"activeCount":87},[],{"trials":828,"activeCount":87},[],{"trials":830,"activeCount":87},[],{"trials":832,"activeCount":87},[833],{"nctId":728,"briefTitle":729,"status":194,"phases":834,"primaryCompletion":731,"completion":731,"start":714,"enrollment":732,"conditions":835,"interventions":836},[79],[23,33],[670,735,736,737],{"trials":838,"activeCount":87},[],{"trials":840,"activeCount":87},[],{"intervention":737,"totalTrials":127,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":855,"NA":857},{"trials":844,"activeCount":87},[],{"trials":846,"activeCount":87},[],{"trials":848,"activeCount":87},[],{"trials":850,"activeCount":87},[851],{"nctId":728,"briefTitle":729,"status":194,"phases":852,"primaryCompletion":731,"completion":731,"start":714,"enrollment":732,"conditions":853,"interventions":854},[79],[23,33],[670,735,736,737],{"trials":856,"activeCount":87},[],{"trials":858,"activeCount":87},[],{"intervention":624,"totalTrials":31,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":877,"PHASE3":888,"PHASE4":890,"NA":892},{"trials":862,"activeCount":87},[],{"trials":864,"activeCount":87},[865,869],{"nctId":616,"briefTitle":617,"status":194,"phases":866,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":867,"interventions":868},[77],[14],[624,597,625,626],{"nctId":870,"briefTitle":871,"status":194,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":216,"conditions":875,"interventions":876},"NCT06094712","A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects",[77],"2016-04-27","2016-04-07",[14],[624],{"trials":878,"activeCount":87},[879],{"nctId":880,"briefTitle":881,"status":194,"phases":882,"primaryCompletion":883,"completion":883,"start":884,"enrollment":885,"conditions":886,"interventions":887},"NCT02804750","Study to Evaluate CORT125134 in Participants With Cushing's Syndrome",[78],"2018-09","2016-06",35,[17],[624],{"trials":889,"activeCount":87},[],{"trials":891,"activeCount":87},[],{"trials":893,"activeCount":87},[],{"intervention":895,"totalTrials":127,"cells":896},"Miricorlilant",{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":898,"activeCount":87},[],{"trials":900,"activeCount":87},[],{"trials":902,"activeCount":87},[903],{"nctId":904,"briefTitle":905,"status":194,"phases":906,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":912},"NCT04524403","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)",[78],"2022-07-29","2022-08-25","2020-09-09",150,[249],[895,895],{"trials":914,"activeCount":87},[],{"trials":916,"activeCount":87},[],{"trials":918,"activeCount":87},[],{"intervention":920,"totalTrials":127,"cells":921},"Relacorilant with nab-paclitaxel",{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":923,"activeCount":87},[],{"trials":925,"activeCount":87},[],{"trials":927,"activeCount":87},[928],{"nctId":929,"briefTitle":930,"status":194,"phases":931,"primaryCompletion":932,"completion":933,"start":934,"enrollment":935,"conditions":936,"interventions":938},"NCT02762981","Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors",[77,78],"2020-05-12","2020-09-12","2016-05-23",85,[937],"Solid Tumors",[920],{"trials":940,"activeCount":87},[],{"trials":942,"activeCount":87},[],{"trials":944,"activeCount":87},[],{"intervention":946,"totalTrials":127,"cells":947},"Exicorilant",{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":949,"activeCount":87},[],{"trials":951,"activeCount":87},[],{"trials":953,"activeCount":87},[954],{"nctId":955,"briefTitle":956,"status":233,"phases":957,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":962,"interventions":964},"NCT03437941","Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer",[77,78],"2021-10-13","2023-01-12","2018-02-20",39,[963],"Metastatic Castration-Resistant Prostate Cancer",[946,965],"Enzalutamide",{"trials":967,"activeCount":87},[],{"trials":969,"activeCount":87},[],{"trials":971,"activeCount":87},[],{"intervention":965,"totalTrials":127,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":978,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":975,"activeCount":87},[],{"trials":977,"activeCount":87},[],{"trials":979,"activeCount":87},[980],{"nctId":955,"briefTitle":956,"status":233,"phases":981,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":982,"interventions":983},[77,78],[963],[946,965],{"trials":985,"activeCount":87},[],{"trials":987,"activeCount":87},[],{"trials":989,"activeCount":87},[],{"intervention":625,"totalTrials":11,"cells":991},{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1059},{"trials":993,"activeCount":87},[],{"trials":995,"activeCount":87},[996,1019,1029,1033,1043],{"nctId":997,"briefTitle":998,"status":194,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT03315338","First-in-human Study in Healthy Subjects",[77],"2019-02-22","2017-09-15",143,[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],"CORT118335, 25 mg","Prednisone Oral","CORT118335, 75mg","CORT118335, 225mg","CORT118335, 675mg","CORT118335, 600mg","CORT118335, 630mg","CORT118335, 375mg","CORT118335, 100mg","CORT118335, 300mg","CORT118335, 900mg","CORT118335, 150mg","CORT118335, 1500mg","CORT118335, dose to be determined",{"nctId":1020,"briefTitle":1021,"status":194,"phases":1022,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1027},"NCT04672512","Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants",[77],"2022-01-17","2020-10-23",115,[14],[1028,625],"CORT125329 lipid capsule formulation",{"nctId":616,"briefTitle":617,"status":194,"phases":1030,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1031,"interventions":1032},[77],[14],[624,597,625,626],{"nctId":1034,"briefTitle":1035,"status":194,"phases":1036,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1041},"NCT05003713","Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants",[77],"2023-02-03","2021-08-03",82,[14],[1042,625],"CORT125236",{"nctId":1044,"briefTitle":1045,"status":194,"phases":1046,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":1049,"conditions":1050,"interventions":1051},"NCT04249323","Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants",[77],"2020-10-15","2020-01-27",110,[30],[1052,625],"CORT113176 Lipid Capsule Formulation",{"trials":1054,"activeCount":87},[],{"trials":1056,"activeCount":87},[],{"trials":1058,"activeCount":87},[],{"trials":1060,"activeCount":87},[],{"intervention":626,"totalTrials":114,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1064,"activeCount":87},[],{"trials":1066,"activeCount":87},[1067,1071],{"nctId":997,"briefTitle":998,"status":194,"phases":1068,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1069,"interventions":1070},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"nctId":616,"briefTitle":617,"status":194,"phases":1072,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":1073,"interventions":1074},[77],[14],[624,597,625,626],{"trials":1076,"activeCount":87},[],{"trials":1078,"activeCount":87},[],{"trials":1080,"activeCount":87},[],{"trials":1082,"activeCount":87},[],{"intervention":394,"totalTrials":114,"cells":1084},{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1111},{"trials":1086,"activeCount":87},[],{"trials":1088,"activeCount":87},[1089,1093],{"nctId":386,"briefTitle":387,"status":194,"phases":1090,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":1091,"interventions":1092},[77],[30],[379,394],{"nctId":1094,"briefTitle":1095,"status":194,"phases":1096,"primaryCompletion":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1102},"NCT03512548","Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites",[77],"2019-07-29","2019-08-23","2018-04-10",52,[14],[1103,394,1104],"Relacorilant 350mg","Relacorilant 300mg",{"trials":1106,"activeCount":87},[],{"trials":1108,"activeCount":87},[],{"trials":1110,"activeCount":87},[],{"trials":1112,"activeCount":87},[],{"intervention":1114,"totalTrials":114,"cells":1115},"CORT118335",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1142,"PHASE3":1144,"PHASE4":1146,"NA":1148},{"trials":1117,"activeCount":87},[],{"trials":1119,"activeCount":87},[1120,1130],{"nctId":1121,"briefTitle":1122,"status":194,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":237,"conditions":1126,"interventions":1127},"NCT03878264","Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants",[77],"2019-03-24","2018-08-06",[14],[1114,1128,1129],"14C-CORT118335 intravenous","14C-CORT118335",{"nctId":1131,"briefTitle":1132,"status":194,"phases":1133,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT03877562","The Effect of CORT118335 on Olanzapine-Induced Weight Gain",[77],"2020-03-13","2020-03-25","2019-04-01",96,[1139],"Antipsychotic-induced Weight Gain",[1141,1114],"Olanzapine",{"trials":1143,"activeCount":87},[],{"trials":1145,"activeCount":87},[],{"trials":1147,"activeCount":87},[],{"trials":1149,"activeCount":87},[],{"intervention":1151,"totalTrials":114,"cells":1152},"Miricorilant 150 mg",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1154,"activeCount":87},[],{"trials":1156,"activeCount":87},[1157,1169],{"nctId":1158,"briefTitle":1159,"status":194,"phases":1160,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1165},"NCT05117489","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)",[77],"2024-01-29","2021-11-23",70,[20],[1151,1166,1167,1168],"Miricorilant 100 mg","Miricorilant 50 mg","Miricorilant 10 mg",{"nctId":1170,"briefTitle":1171,"status":194,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":309,"conditions":1175,"interventions":1176},"NCT04672499","Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants",[77],"2020-09-07","2020-04-27",[14],[1177,1151],"Miricorilant 300 mg",{"trials":1179,"activeCount":87},[],{"trials":1181,"activeCount":87},[],{"trials":1183,"activeCount":87},[],{"trials":1185,"activeCount":87},[],{"intervention":1005,"totalTrials":127,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1196,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1189,"activeCount":87},[],{"trials":1191,"activeCount":87},[1192],{"nctId":997,"briefTitle":998,"status":194,"phases":1193,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1194,"interventions":1195},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1197,"activeCount":87},[],{"trials":1199,"activeCount":87},[],{"trials":1201,"activeCount":87},[],{"trials":1203,"activeCount":87},[],{"intervention":1007,"totalTrials":127,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1207,"activeCount":87},[],{"trials":1209,"activeCount":87},[1210],{"nctId":997,"briefTitle":998,"status":194,"phases":1211,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1212,"interventions":1213},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1215,"activeCount":87},[],{"trials":1217,"activeCount":87},[],{"trials":1219,"activeCount":87},[],{"trials":1221,"activeCount":87},[],{"intervention":1008,"totalTrials":127,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1225,"activeCount":87},[],{"trials":1227,"activeCount":87},[1228],{"nctId":997,"briefTitle":998,"status":194,"phases":1229,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1230,"interventions":1231},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1233,"activeCount":87},[],{"trials":1235,"activeCount":87},[],{"trials":1237,"activeCount":87},[],{"trials":1239,"activeCount":87},[],{"intervention":1009,"totalTrials":127,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1243,"activeCount":87},[],{"trials":1245,"activeCount":87},[1246],{"nctId":997,"briefTitle":998,"status":194,"phases":1247,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1248,"interventions":1249},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1251,"activeCount":87},[],{"trials":1253,"activeCount":87},[],{"trials":1255,"activeCount":87},[],{"trials":1257,"activeCount":87},[],{"intervention":1010,"totalTrials":127,"cells":1259},{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1261,"activeCount":87},[],{"trials":1263,"activeCount":87},[1264],{"nctId":997,"briefTitle":998,"status":194,"phases":1265,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1266,"interventions":1267},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1269,"activeCount":87},[],{"trials":1271,"activeCount":87},[],{"trials":1273,"activeCount":87},[],{"trials":1275,"activeCount":87},[],{"intervention":1011,"totalTrials":127,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":87},[],{"trials":1281,"activeCount":87},[1282],{"nctId":997,"briefTitle":998,"status":194,"phases":1283,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1284,"interventions":1285},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1287,"activeCount":87},[],{"trials":1289,"activeCount":87},[],{"trials":1291,"activeCount":87},[],{"trials":1293,"activeCount":87},[],{"intervention":1012,"totalTrials":127,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1304,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":87},[],{"trials":1299,"activeCount":87},[1300],{"nctId":997,"briefTitle":998,"status":194,"phases":1301,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1302,"interventions":1303},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1305,"activeCount":87},[],{"trials":1307,"activeCount":87},[],{"trials":1309,"activeCount":87},[],{"trials":1311,"activeCount":87},[],{"intervention":1013,"totalTrials":127,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1322,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1315,"activeCount":87},[],{"trials":1317,"activeCount":87},[1318],{"nctId":997,"briefTitle":998,"status":194,"phases":1319,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1320,"interventions":1321},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1323,"activeCount":87},[],{"trials":1325,"activeCount":87},[],{"trials":1327,"activeCount":87},[],{"trials":1329,"activeCount":87},[],{"intervention":1014,"totalTrials":127,"cells":1331},{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1340,"PHASE3":1342,"PHASE4":1344,"NA":1346},{"trials":1333,"activeCount":87},[],{"trials":1335,"activeCount":87},[1336],{"nctId":997,"briefTitle":998,"status":194,"phases":1337,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1338,"interventions":1339},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1341,"activeCount":87},[],{"trials":1343,"activeCount":87},[],{"trials":1345,"activeCount":87},[],{"trials":1347,"activeCount":87},[],{"intervention":1015,"totalTrials":127,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1358,"PHASE3":1360,"PHASE4":1362,"NA":1364},{"trials":1351,"activeCount":87},[],{"trials":1353,"activeCount":87},[1354],{"nctId":997,"briefTitle":998,"status":194,"phases":1355,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1356,"interventions":1357},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1359,"activeCount":87},[],{"trials":1361,"activeCount":87},[],{"trials":1363,"activeCount":87},[],{"trials":1365,"activeCount":87},[],{"intervention":1016,"totalTrials":127,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1376,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1369,"activeCount":87},[],{"trials":1371,"activeCount":87},[1372],{"nctId":997,"briefTitle":998,"status":194,"phases":1373,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1374,"interventions":1375},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1377,"activeCount":87},[],{"trials":1379,"activeCount":87},[],{"trials":1381,"activeCount":87},[],{"trials":1383,"activeCount":87},[],{"intervention":1017,"totalTrials":127,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1400},{"trials":1387,"activeCount":87},[],{"trials":1389,"activeCount":87},[1390],{"nctId":997,"briefTitle":998,"status":194,"phases":1391,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1392,"interventions":1393},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1395,"activeCount":87},[],{"trials":1397,"activeCount":87},[],{"trials":1399,"activeCount":87},[],{"trials":1401,"activeCount":87},[],{"intervention":1018,"totalTrials":127,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1412,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1405,"activeCount":87},[],{"trials":1407,"activeCount":87},[1408],{"nctId":997,"briefTitle":998,"status":194,"phases":1409,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1410,"interventions":1411},[77],[14],[1005,1006,626,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018],{"trials":1413,"activeCount":87},[],{"trials":1415,"activeCount":87},[],{"trials":1417,"activeCount":87},[],{"trials":1419,"activeCount":87},[],{"intervention":275,"totalTrials":127,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1423,"activeCount":87},[],{"trials":1425,"activeCount":87},[1426],{"nctId":266,"briefTitle":267,"status":194,"phases":1427,"primaryCompletion":269,"completion":270,"start":271,"enrollment":185,"conditions":1428,"interventions":1429},[77],[273],[258,275],{"trials":1431,"activeCount":87},[],{"trials":1433,"activeCount":87},[],{"trials":1435,"activeCount":87},[],{"trials":1437,"activeCount":87},[],{"intervention":286,"totalTrials":127,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1454},{"trials":1441,"activeCount":87},[],{"trials":1443,"activeCount":87},[1444],{"nctId":277,"briefTitle":278,"status":194,"phases":1445,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":1446,"interventions":1447},[77],[14],[286,287,288,289,290,258],{"trials":1449,"activeCount":87},[],{"trials":1451,"activeCount":87},[],{"trials":1453,"activeCount":87},[],{"trials":1455,"activeCount":87},[],{"intervention":287,"totalTrials":127,"cells":1457},{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1466,"PHASE3":1468,"PHASE4":1470,"NA":1472},{"trials":1459,"activeCount":87},[],{"trials":1461,"activeCount":87},[1462],{"nctId":277,"briefTitle":278,"status":194,"phases":1463,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":1464,"interventions":1465},[77],[14],[286,287,288,289,290,258],{"trials":1467,"activeCount":87},[],{"trials":1469,"activeCount":87},[],{"trials":1471,"activeCount":87},[],{"trials":1473,"activeCount":87},[],{"intervention":288,"totalTrials":127,"cells":1475},{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1477,"activeCount":87},[],{"trials":1479,"activeCount":87},[1480],{"nctId":277,"briefTitle":278,"status":194,"phases":1481,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":1482,"interventions":1483},[77],[14],[286,287,288,289,290,258],{"trials":1485,"activeCount":87},[],{"trials":1487,"activeCount":87},[],{"trials":1489,"activeCount":87},[],{"trials":1491,"activeCount":87},[],{"intervention":289,"totalTrials":127,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1502,"PHASE3":1504,"PHASE4":1506,"NA":1508},{"trials":1495,"activeCount":87},[],{"trials":1497,"activeCount":87},[1498],{"nctId":277,"briefTitle":278,"status":194,"phases":1499,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":1500,"interventions":1501},[77],[14],[286,287,288,289,290,258],{"trials":1503,"activeCount":87},[],{"trials":1505,"activeCount":87},[],{"trials":1507,"activeCount":87},[],{"trials":1509,"activeCount":87},[],{"intervention":290,"totalTrials":127,"cells":1511},{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1513,"activeCount":87},[],{"trials":1515,"activeCount":87},[1516],{"nctId":277,"briefTitle":278,"status":194,"phases":1517,"primaryCompletion":280,"completion":281,"start":282,"enrollment":283,"conditions":1518,"interventions":1519},[77],[14],[286,287,288,289,290,258],{"trials":1521,"activeCount":87},[],{"trials":1523,"activeCount":87},[],{"trials":1525,"activeCount":87},[],{"trials":1527,"activeCount":87},[],{"intervention":612,"totalTrials":127,"cells":1529},{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1544},{"trials":1531,"activeCount":87},[],{"trials":1533,"activeCount":87},[1534],{"nctId":604,"briefTitle":605,"status":194,"phases":1535,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":1536,"interventions":1537},[77],[14],[612,597,613,614],{"trials":1539,"activeCount":87},[],{"trials":1541,"activeCount":87},[],{"trials":1543,"activeCount":87},[],{"trials":1545,"activeCount":87},[],{"intervention":613,"totalTrials":127,"cells":1547},{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1556,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1549,"activeCount":87},[],{"trials":1551,"activeCount":87},[1552],{"nctId":604,"briefTitle":605,"status":194,"phases":1553,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":1554,"interventions":1555},[77],[14],[612,597,613,614],{"trials":1557,"activeCount":87},[],{"trials":1559,"activeCount":87},[],{"trials":1561,"activeCount":87},[],{"trials":1563,"activeCount":87},[],{"intervention":614,"totalTrials":127,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1574,"PHASE3":1576,"PHASE4":1578,"NA":1580},{"trials":1567,"activeCount":87},[],{"trials":1569,"activeCount":87},[1570],{"nctId":604,"briefTitle":605,"status":194,"phases":1571,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":1572,"interventions":1573},[77],[14],[612,597,613,614],{"trials":1575,"activeCount":87},[],{"trials":1577,"activeCount":87},[],{"trials":1579,"activeCount":87},[],{"trials":1581,"activeCount":87},[],{"intervention":301,"totalTrials":127,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1592,"PHASE3":1594,"PHASE4":1596,"NA":1598},{"trials":1585,"activeCount":87},[],{"trials":1587,"activeCount":87},[1588],{"nctId":292,"briefTitle":293,"status":194,"phases":1589,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":1590,"interventions":1591},[77],[26,299],[301,258],{"trials":1593,"activeCount":87},[],{"trials":1595,"activeCount":87},[],{"trials":1597,"activeCount":87},[],{"trials":1599,"activeCount":87},[],{"intervention":312,"totalTrials":127,"cells":1601},{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1610,"PHASE3":1612,"PHASE4":1614,"NA":1616},{"trials":1603,"activeCount":87},[],{"trials":1605,"activeCount":87},[1606],{"nctId":303,"briefTitle":304,"status":194,"phases":1607,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":1608,"interventions":1609},[77],[14],[258,312],{"trials":1611,"activeCount":87},[],{"trials":1613,"activeCount":87},[],{"trials":1615,"activeCount":87},[],{"trials":1617,"activeCount":87},[],{"intervention":1028,"totalTrials":127,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1628,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1621,"activeCount":87},[],{"trials":1623,"activeCount":87},[1624],{"nctId":1020,"briefTitle":1021,"status":194,"phases":1625,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":1025,"conditions":1626,"interventions":1627},[77],[14],[1028,625],{"trials":1629,"activeCount":87},[],{"trials":1631,"activeCount":87},[],{"trials":1633,"activeCount":87},[],{"trials":1635,"activeCount":87},[],{"intervention":1637,"totalTrials":127,"cells":1638},"Relacorilant Fasted",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1640,"activeCount":87},[],{"trials":1642,"activeCount":87},[1643],{"nctId":1644,"briefTitle":1645,"status":194,"phases":1646,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":297,"conditions":1650,"interventions":1652},"NCT03442621","Relacorilant Food Effect Study in Healthy Subjects",[77],"2018-02-28","2018-03-09","2018-01-16",[14,1651],"Food-drug Interaction",[1637,1653,1654],"Relacorilant with a high fat breakfast","Relacorilant with a moderate breakfast",{"trials":1656,"activeCount":87},[],{"trials":1658,"activeCount":87},[],{"trials":1660,"activeCount":87},[],{"trials":1662,"activeCount":87},[],{"intervention":1653,"totalTrials":127,"cells":1664},{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1673,"PHASE3":1675,"PHASE4":1677,"NA":1679},{"trials":1666,"activeCount":87},[],{"trials":1668,"activeCount":87},[1669],{"nctId":1644,"briefTitle":1645,"status":194,"phases":1670,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":297,"conditions":1671,"interventions":1672},[77],[14,1651],[1637,1653,1654],{"trials":1674,"activeCount":87},[],{"trials":1676,"activeCount":87},[],{"trials":1678,"activeCount":87},[],{"trials":1680,"activeCount":87},[],{"intervention":1654,"totalTrials":127,"cells":1682},{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1691,"PHASE3":1693,"PHASE4":1695,"NA":1697},{"trials":1684,"activeCount":87},[],{"trials":1686,"activeCount":87},[1687],{"nctId":1644,"briefTitle":1645,"status":194,"phases":1688,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":297,"conditions":1689,"interventions":1690},[77],[14,1651],[1637,1653,1654],{"trials":1692,"activeCount":87},[],{"trials":1694,"activeCount":87},[],{"trials":1696,"activeCount":87},[],{"trials":1698,"activeCount":87},[],{"intervention":1700,"totalTrials":127,"cells":1701},"Relacorilant under fasted conditions",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1703,"activeCount":87},[],{"trials":1705,"activeCount":87},[1706],{"nctId":1707,"briefTitle":1708,"status":194,"phases":1709,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":297,"conditions":1712,"interventions":1713},"NCT06094738","A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects",[77],"2020-11-16","2020-09-19",[14],[1700,1714,1715],"Relacorilant after a high-fat meal","Relacorilant after a low-fat meal",{"trials":1717,"activeCount":87},[],{"trials":1719,"activeCount":87},[],{"trials":1721,"activeCount":87},[],{"trials":1723,"activeCount":87},[],{"intervention":1714,"totalTrials":127,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1727,"activeCount":87},[],{"trials":1729,"activeCount":87},[1730],{"nctId":1707,"briefTitle":1708,"status":194,"phases":1731,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":297,"conditions":1732,"interventions":1733},[77],[14],[1700,1714,1715],{"trials":1735,"activeCount":87},[],{"trials":1737,"activeCount":87},[],{"trials":1739,"activeCount":87},[],{"trials":1741,"activeCount":87},[],{"intervention":1715,"totalTrials":127,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1745,"activeCount":87},[],{"trials":1747,"activeCount":87},[1748],{"nctId":1707,"briefTitle":1708,"status":194,"phases":1749,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":297,"conditions":1750,"interventions":1751},[77],[14],[1700,1714,1715],{"trials":1753,"activeCount":87},[],{"trials":1755,"activeCount":87},[],{"trials":1757,"activeCount":87},[],{"trials":1759,"activeCount":87},[],{"intervention":1761,"totalTrials":127,"cells":1762},"Miricorilant Treatment A",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1779,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1764,"activeCount":87},[],{"trials":1766,"activeCount":87},[1767],{"nctId":1768,"briefTitle":1769,"status":194,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":1773,"conditions":1774,"interventions":1775},"NCT07240116","Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects",[77],"2026-03-03","2025-09-11",18,[14],[1761,1776,1777,1778],"Miricorilant Treatment B","Miricorilant Treatment C","Miricorilant Treatment D",{"trials":1780,"activeCount":87},[],{"trials":1782,"activeCount":87},[],{"trials":1784,"activeCount":87},[],{"trials":1786,"activeCount":87},[],{"intervention":1776,"totalTrials":127,"cells":1788},{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1797,"PHASE3":1799,"PHASE4":1801,"NA":1803},{"trials":1790,"activeCount":87},[],{"trials":1792,"activeCount":87},[1793],{"nctId":1768,"briefTitle":1769,"status":194,"phases":1794,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":1773,"conditions":1795,"interventions":1796},[77],[14],[1761,1776,1777,1778],{"trials":1798,"activeCount":87},[],{"trials":1800,"activeCount":87},[],{"trials":1802,"activeCount":87},[],{"trials":1804,"activeCount":87},[],{"intervention":1777,"totalTrials":127,"cells":1806},{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1815,"PHASE3":1817,"PHASE4":1819,"NA":1821},{"trials":1808,"activeCount":87},[],{"trials":1810,"activeCount":87},[1811],{"nctId":1768,"briefTitle":1769,"status":194,"phases":1812,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":1773,"conditions":1813,"interventions":1814},[77],[14],[1761,1776,1777,1778],{"trials":1816,"activeCount":87},[],{"trials":1818,"activeCount":87},[],{"trials":1820,"activeCount":87},[],{"trials":1822,"activeCount":87},[],{"intervention":1778,"totalTrials":127,"cells":1824},{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1833,"PHASE3":1835,"PHASE4":1837,"NA":1839},{"trials":1826,"activeCount":87},[],{"trials":1828,"activeCount":87},[1829],{"nctId":1768,"briefTitle":1769,"status":194,"phases":1830,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":1773,"conditions":1831,"interventions":1832},[77],[14],[1761,1776,1777,1778],{"trials":1834,"activeCount":87},[],{"trials":1836,"activeCount":87},[],{"trials":1838,"activeCount":87},[],{"trials":1840,"activeCount":87},[],{"intervention":1842,"totalTrials":127,"cells":1843},"Mifepristone 300 MG",{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1845,"activeCount":87},[],{"trials":1847,"activeCount":87},[1848],{"nctId":1849,"briefTitle":1850,"status":194,"phases":1851,"primaryCompletion":1852,"completion":1852,"start":1853,"enrollment":1854,"conditions":1855,"interventions":1857},"NCT03259542","Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor",[77],"2017-12-11","2017-08-09",33,[1856,14],"Drug Interaction Potentiation",[1842,1858],"Itraconazole 100 MG",{"trials":1860,"activeCount":87},[],{"trials":1862,"activeCount":87},[],{"trials":1864,"activeCount":87},[],{"trials":1866,"activeCount":87},[],{"intervention":1858,"totalTrials":127,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1870,"activeCount":87},[],{"trials":1872,"activeCount":87},[1873],{"nctId":1849,"briefTitle":1850,"status":194,"phases":1874,"primaryCompletion":1852,"completion":1852,"start":1853,"enrollment":1854,"conditions":1875,"interventions":1876},[77],[1856,14],[1842,1858],{"trials":1878,"activeCount":87},[],{"trials":1880,"activeCount":87},[],{"trials":1882,"activeCount":87},[],{"trials":1884,"activeCount":87},[],{"intervention":1886,"totalTrials":127,"cells":1887},"mifepristone + fluvastatin",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1901,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1889,"activeCount":87},[],{"trials":1891,"activeCount":87},[1892],{"nctId":1893,"briefTitle":1894,"status":194,"phases":1895,"primaryCompletion":608,"completion":608,"start":1896,"enrollment":1897,"conditions":1898,"interventions":1900},"NCT00752843","A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers",[77],"2008-09",20,[1899],"Healthy Subjects",[1886],{"trials":1902,"activeCount":87},[],{"trials":1904,"activeCount":87},[],{"trials":1906,"activeCount":87},[],{"trials":1908,"activeCount":87},[],{"intervention":1103,"totalTrials":127,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1919,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1912,"activeCount":87},[],{"trials":1914,"activeCount":87},[1915],{"nctId":1094,"briefTitle":1095,"status":194,"phases":1916,"primaryCompletion":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":1917,"interventions":1918},[77],[14],[1103,394,1104],{"trials":1920,"activeCount":87},[],{"trials":1922,"activeCount":87},[],{"trials":1924,"activeCount":87},[],{"trials":1926,"activeCount":87},[],{"intervention":1104,"totalTrials":127,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1937,"PHASE3":1939,"PHASE4":1941,"NA":1943},{"trials":1930,"activeCount":87},[],{"trials":1932,"activeCount":87},[1933],{"nctId":1094,"briefTitle":1095,"status":194,"phases":1934,"primaryCompletion":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":1935,"interventions":1936},[77],[14],[1103,394,1104],{"trials":1938,"activeCount":87},[],{"trials":1940,"activeCount":87},[],{"trials":1942,"activeCount":87},[],{"trials":1944,"activeCount":87},[],{"intervention":1946,"totalTrials":127,"cells":1947},"Mifepristone and Eribulin in combination",{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1968,"PHASE3":1970,"PHASE4":1972,"NA":1974},{"trials":1949,"activeCount":87},[],{"trials":1951,"activeCount":87},[1952],{"nctId":1953,"briefTitle":1954,"status":194,"phases":1955,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1967},"NCT02014337","Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors",[77],"2017-12","2014-01",37,[1960,1961,1962,1963,1964,1965,1966],"Breast Cancer","Ovarian Epithelial Cancer Recurrent","Sarcoma","Non-small Cell Lung Cancer","Carcinoma, Transitional Cell","Prostate Cancer","Prostatic Neoplasms",[1946],{"trials":1969,"activeCount":87},[],{"trials":1971,"activeCount":87},[],{"trials":1973,"activeCount":87},[],{"trials":1975,"activeCount":87},[],{"intervention":1977,"totalTrials":127,"cells":1978},"CORT125134 150 mg",{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1994,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1980,"activeCount":87},[],{"trials":1982,"activeCount":87},[1983],{"nctId":1984,"briefTitle":1985,"status":194,"phases":1986,"primaryCompletion":1987,"completion":1987,"start":1988,"enrollment":1989,"conditions":1990,"interventions":1991},"NCT06094790","A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects",[77],"2017-11-15","2017-05-18",32,[14],[1977,1992,1993],"CORT125134 250 mg","CORT125134 dose to be determined",{"trials":1995,"activeCount":87},[],{"trials":1997,"activeCount":87},[],{"trials":1999,"activeCount":87},[],{"trials":2001,"activeCount":87},[],{"intervention":1992,"totalTrials":127,"cells":2003},{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2005,"activeCount":87},[],{"trials":2007,"activeCount":87},[2008],{"nctId":1984,"briefTitle":1985,"status":194,"phases":2009,"primaryCompletion":1987,"completion":1987,"start":1988,"enrollment":1989,"conditions":2010,"interventions":2011},[77],[14],[1977,1992,1993],{"trials":2013,"activeCount":87},[],{"trials":2015,"activeCount":87},[],{"trials":2017,"activeCount":87},[],{"trials":2019,"activeCount":87},[],{"intervention":1993,"totalTrials":127,"cells":2021},{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2023,"activeCount":87},[],{"trials":2025,"activeCount":87},[2026],{"nctId":1984,"briefTitle":1985,"status":194,"phases":2027,"primaryCompletion":1987,"completion":1987,"start":1988,"enrollment":1989,"conditions":2028,"interventions":2029},[77],[14],[1977,1992,1993],{"trials":2031,"activeCount":87},[],{"trials":2033,"activeCount":87},[],{"trials":2035,"activeCount":87},[],{"trials":2037,"activeCount":87},[],{"intervention":2039,"totalTrials":127,"cells":2040},"[14C]-CORT125134",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2053,"PHASE3":2055,"PHASE4":2057,"NA":2059},{"trials":2042,"activeCount":87},[],{"trials":2044,"activeCount":87},[2045],{"nctId":2046,"briefTitle":2047,"status":194,"phases":2048,"primaryCompletion":2049,"completion":2049,"start":2050,"enrollment":8,"conditions":2051,"interventions":2052},"NCT03067376","A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body",[77],"2016-09","2016-08",[14],[2039],{"trials":2054,"activeCount":87},[],{"trials":2056,"activeCount":87},[],{"trials":2058,"activeCount":87},[],{"trials":2060,"activeCount":87},[],{"intervention":2062,"totalTrials":127,"cells":2063},"14C-CORT125281",{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2077,"PHASE3":2079,"PHASE4":2081,"NA":2083},{"trials":2065,"activeCount":87},[],{"trials":2067,"activeCount":87},[2068],{"nctId":2069,"briefTitle":2070,"status":194,"phases":2071,"primaryCompletion":2072,"completion":2073,"start":2074,"enrollment":21,"conditions":2075,"interventions":2076},"NCT03877952","Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants",[77],"2018-11-01","2018-11-02","2018-09-13",[14],[2062],{"trials":2078,"activeCount":87},[],{"trials":2080,"activeCount":87},[],{"trials":2082,"activeCount":87},[],{"trials":2084,"activeCount":87},[],{"intervention":2086,"totalTrials":127,"cells":2087},"CORT125281, 40mg, fasted",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2112,"PHASE3":2114,"PHASE4":2116,"NA":2118},{"trials":2089,"activeCount":87},[],{"trials":2091,"activeCount":87},[2092],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2095,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2099,"interventions":2100},"NCT03335956","CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)",[77],"2018-05-31","2018-06-25","2017-09-21",[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],"Prednisone 25mg, fasted","Pioglitazone 15mg","Prednisone 25mg, fed","CORT125281, 120mg, fasted","CORT125281, 360mg, fasted","CORT125281, 720mg, fasted","CORT125281, 360mg, fed","CORT125281, 360mg","CORT125281, 120mg","CORT125281, 180mg","CORT125281, 240mg",{"trials":2113,"activeCount":87},[],{"trials":2115,"activeCount":87},[],{"trials":2117,"activeCount":87},[],{"trials":2119,"activeCount":87},[],{"intervention":2101,"totalTrials":127,"cells":2121},{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2123,"activeCount":87},[],{"trials":2125,"activeCount":87},[2126],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2127,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2128,"interventions":2129},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2131,"activeCount":87},[],{"trials":2133,"activeCount":87},[],{"trials":2135,"activeCount":87},[],{"trials":2137,"activeCount":87},[],{"intervention":2102,"totalTrials":127,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2148,"PHASE3":2150,"PHASE4":2152,"NA":2154},{"trials":2141,"activeCount":87},[],{"trials":2143,"activeCount":87},[2144],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2145,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2146,"interventions":2147},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2149,"activeCount":87},[],{"trials":2151,"activeCount":87},[],{"trials":2153,"activeCount":87},[],{"trials":2155,"activeCount":87},[],{"intervention":2103,"totalTrials":127,"cells":2157},{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2166,"PHASE3":2168,"PHASE4":2170,"NA":2172},{"trials":2159,"activeCount":87},[],{"trials":2161,"activeCount":87},[2162],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2163,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2164,"interventions":2165},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2167,"activeCount":87},[],{"trials":2169,"activeCount":87},[],{"trials":2171,"activeCount":87},[],{"trials":2173,"activeCount":87},[],{"intervention":2104,"totalTrials":127,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2184,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":87},[],{"trials":2179,"activeCount":87},[2180],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2181,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2182,"interventions":2183},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2185,"activeCount":87},[],{"trials":2187,"activeCount":87},[],{"trials":2189,"activeCount":87},[],{"trials":2191,"activeCount":87},[],{"intervention":2105,"totalTrials":127,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2195,"activeCount":87},[],{"trials":2197,"activeCount":87},[2198],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2199,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2200,"interventions":2201},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2203,"activeCount":87},[],{"trials":2205,"activeCount":87},[],{"trials":2207,"activeCount":87},[],{"trials":2209,"activeCount":87},[],{"intervention":2106,"totalTrials":127,"cells":2211},{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2220,"PHASE3":2222,"PHASE4":2224,"NA":2226},{"trials":2213,"activeCount":87},[],{"trials":2215,"activeCount":87},[2216],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2217,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2218,"interventions":2219},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2221,"activeCount":87},[],{"trials":2223,"activeCount":87},[],{"trials":2225,"activeCount":87},[],{"trials":2227,"activeCount":87},[],{"intervention":2107,"totalTrials":127,"cells":2229},{"EARLY_PHASE1":2230,"PHASE1":2232,"PHASE2":2238,"PHASE3":2240,"PHASE4":2242,"NA":2244},{"trials":2231,"activeCount":87},[],{"trials":2233,"activeCount":87},[2234],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2235,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2236,"interventions":2237},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2239,"activeCount":87},[],{"trials":2241,"activeCount":87},[],{"trials":2243,"activeCount":87},[],{"trials":2245,"activeCount":87},[],{"intervention":2108,"totalTrials":127,"cells":2247},{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2256,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2249,"activeCount":87},[],{"trials":2251,"activeCount":87},[2252],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2253,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2254,"interventions":2255},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2257,"activeCount":87},[],{"trials":2259,"activeCount":87},[],{"trials":2261,"activeCount":87},[],{"trials":2263,"activeCount":87},[],{"intervention":2109,"totalTrials":127,"cells":2265},{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2280},{"trials":2267,"activeCount":87},[],{"trials":2269,"activeCount":87},[2270],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2271,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2272,"interventions":2273},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2275,"activeCount":87},[],{"trials":2277,"activeCount":87},[],{"trials":2279,"activeCount":87},[],{"trials":2281,"activeCount":87},[],{"intervention":2110,"totalTrials":127,"cells":2283},{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2292,"PHASE3":2294,"PHASE4":2296,"NA":2298},{"trials":2285,"activeCount":87},[],{"trials":2287,"activeCount":87},[2288],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2289,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2290,"interventions":2291},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2293,"activeCount":87},[],{"trials":2295,"activeCount":87},[],{"trials":2297,"activeCount":87},[],{"trials":2299,"activeCount":87},[],{"intervention":2111,"totalTrials":127,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2310,"PHASE3":2312,"PHASE4":2314,"NA":2316},{"trials":2303,"activeCount":87},[],{"trials":2305,"activeCount":87},[2306],{"nctId":2093,"briefTitle":2094,"status":194,"phases":2307,"primaryCompletion":2096,"completion":2097,"start":2098,"enrollment":633,"conditions":2308,"interventions":2309},[77],[14],[2086,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2108],{"trials":2311,"activeCount":87},[],{"trials":2313,"activeCount":87},[],{"trials":2315,"activeCount":87},[],{"trials":2317,"activeCount":87},[],{"intervention":1128,"totalTrials":127,"cells":2319},{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2328,"PHASE3":2330,"PHASE4":2332,"NA":2334},{"trials":2321,"activeCount":87},[],{"trials":2323,"activeCount":87},[2324],{"nctId":1121,"briefTitle":1122,"status":194,"phases":2325,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":237,"conditions":2326,"interventions":2327},[77],[14],[1114,1128,1129],{"trials":2329,"activeCount":87},[],{"trials":2331,"activeCount":87},[],{"trials":2333,"activeCount":87},[],{"trials":2335,"activeCount":87},[],{"intervention":1129,"totalTrials":127,"cells":2337},{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2346,"PHASE3":2348,"PHASE4":2350,"NA":2352},{"trials":2339,"activeCount":87},[],{"trials":2341,"activeCount":87},[2342],{"nctId":1121,"briefTitle":1122,"status":194,"phases":2343,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":237,"conditions":2344,"interventions":2345},[77],[14],[1114,1128,1129],{"trials":2347,"activeCount":87},[],{"trials":2349,"activeCount":87},[],{"trials":2351,"activeCount":87},[],{"trials":2353,"activeCount":87},[],{"intervention":1166,"totalTrials":127,"cells":2355},{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2364,"PHASE3":2366,"PHASE4":2368,"NA":2370},{"trials":2357,"activeCount":87},[],{"trials":2359,"activeCount":87},[2360],{"nctId":1158,"briefTitle":1159,"status":194,"phases":2361,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":2362,"interventions":2363},[77],[20],[1151,1166,1167,1168],{"trials":2365,"activeCount":87},[],{"trials":2367,"activeCount":87},[],{"trials":2369,"activeCount":87},[],{"trials":2371,"activeCount":87},[],{"intervention":1167,"totalTrials":127,"cells":2373},{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2382,"PHASE3":2384,"PHASE4":2386,"NA":2388},{"trials":2375,"activeCount":87},[],{"trials":2377,"activeCount":87},[2378],{"nctId":1158,"briefTitle":1159,"status":194,"phases":2379,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":2380,"interventions":2381},[77],[20],[1151,1166,1167,1168],{"trials":2383,"activeCount":87},[],{"trials":2385,"activeCount":87},[],{"trials":2387,"activeCount":87},[],{"trials":2389,"activeCount":87},[],{"intervention":1168,"totalTrials":127,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2400,"PHASE3":2402,"PHASE4":2404,"NA":2406},{"trials":2393,"activeCount":87},[],{"trials":2395,"activeCount":87},[2396],{"nctId":1158,"briefTitle":1159,"status":194,"phases":2397,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":2398,"interventions":2399},[77],[20],[1151,1166,1167,1168],{"trials":2401,"activeCount":87},[],{"trials":2403,"activeCount":87},[],{"trials":2405,"activeCount":87},[],{"trials":2407,"activeCount":87},[],{"intervention":1042,"totalTrials":127,"cells":2409},{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2418,"PHASE3":2420,"PHASE4":2422,"NA":2424},{"trials":2411,"activeCount":87},[],{"trials":2413,"activeCount":87},[2414],{"nctId":1034,"briefTitle":1035,"status":194,"phases":2415,"primaryCompletion":1037,"completion":1037,"start":1038,"enrollment":1039,"conditions":2416,"interventions":2417},[77],[14],[1042,625],{"trials":2419,"activeCount":87},[],{"trials":2421,"activeCount":87},[],{"trials":2423,"activeCount":87},[],{"trials":2425,"activeCount":87},[],{"intervention":1052,"totalTrials":127,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2436,"PHASE3":2438,"PHASE4":2440,"NA":2442},{"trials":2429,"activeCount":87},[],{"trials":2431,"activeCount":87},[2432],{"nctId":1044,"briefTitle":1045,"status":194,"phases":2433,"primaryCompletion":1047,"completion":1047,"start":1048,"enrollment":1049,"conditions":2434,"interventions":2435},[77],[30],[1052,625],{"trials":2437,"activeCount":87},[],{"trials":2439,"activeCount":87},[],{"trials":2441,"activeCount":87},[],{"trials":2443,"activeCount":87},[],{"intervention":2445,"totalTrials":127,"cells":2446},"[14C]-CORT113176",{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2459,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2448,"activeCount":87},[],{"trials":2450,"activeCount":87},[2451],{"nctId":2452,"briefTitle":2453,"status":194,"phases":2454,"primaryCompletion":2455,"completion":2455,"start":2456,"enrollment":21,"conditions":2457,"interventions":2458},"NCT04990310","Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants",[77],"2021-09-20","2021-08-18",[14],[2445],{"trials":2460,"activeCount":87},[],{"trials":2462,"activeCount":87},[],{"trials":2464,"activeCount":87},[],{"trials":2466,"activeCount":87},[],{"intervention":212,"totalTrials":127,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2477,"PHASE3":2479,"PHASE4":2481,"NA":2483},{"trials":2470,"activeCount":87},[],{"trials":2472,"activeCount":87},[2473],{"nctId":203,"briefTitle":204,"status":194,"phases":2474,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":2475,"interventions":2476},[77],[210,200],[44,212],{"trials":2478,"activeCount":87},[],{"trials":2480,"activeCount":87},[],{"trials":2482,"activeCount":87},[],{"trials":2484,"activeCount":87},[],{"intervention":1177,"totalTrials":127,"cells":2486},{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2488,"activeCount":87},[],{"trials":2490,"activeCount":87},[2491],{"nctId":1170,"briefTitle":1171,"status":194,"phases":2492,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":309,"conditions":2493,"interventions":2494},[77],[14],[1177,1151],{"trials":2496,"activeCount":87},[],{"trials":2498,"activeCount":87},[],{"trials":2500,"activeCount":87},[],{"trials":2502,"activeCount":87},[],{"intervention":2504,"totalTrials":127,"cells":2505},"CORT113176",{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2518,"PHASE3":2520,"PHASE4":2522,"NA":2524},{"trials":2507,"activeCount":87},[],{"trials":2509,"activeCount":87},[2510],{"nctId":2511,"briefTitle":2512,"status":194,"phases":2513,"primaryCompletion":2514,"completion":2514,"start":307,"enrollment":2515,"conditions":2516,"interventions":2517},"NCT04994743","Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants",[77],"2021-09-30",16,[30],[2504],{"trials":2519,"activeCount":87},[],{"trials":2521,"activeCount":87},[],{"trials":2523,"activeCount":87},[],{"trials":2525,"activeCount":87},[],{"intervention":1141,"totalTrials":127,"cells":2527},{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2536,"PHASE3":2538,"PHASE4":2540,"NA":2542},{"trials":2529,"activeCount":87},[],{"trials":2531,"activeCount":87},[2532],{"nctId":1131,"briefTitle":1132,"status":194,"phases":2533,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":2534,"interventions":2535},[77],[1139],[1141,1114],{"trials":2537,"activeCount":87},[],{"trials":2539,"activeCount":87},[],{"trials":2541,"activeCount":87},[],{"trials":2543,"activeCount":87},[],{"intervention":2545,"totalTrials":127,"cells":2546},"Cushing's syndrome confirmation",{"EARLY_PHASE1":2547,"PHASE1":2549,"PHASE2":2551,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2548,"activeCount":87},[],{"trials":2550,"activeCount":87},[],{"trials":2552,"activeCount":87},[],{"trials":2554,"activeCount":87},[],{"trials":2556,"activeCount":87},[],{"trials":2558,"activeCount":87},[2559],{"nctId":2560,"briefTitle":2561,"status":233,"phases":2562,"primaryCompletion":2563,"start":607,"enrollment":114,"conditions":2564,"interventions":2565},"NCT00796783","A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia",[],"2010-06",[17],[2545]]